Druck Icon

Lausanne University Hospital Investigates Use of PENTIXAFOR in Cardio-Vascular Setting

Berlin, 01.02.2023. The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting. It is the first time that Eckert & Ziegler’s proprietary CXCR4-compound is used in an advanced clinical test in a non-cancer indication, opening the way for a broader use of PENTIXAFOR outside of oncology.

The Gallium-68 based radio-diagnostic PENTIXAFOR promises to significantly improve the sensitivity in the detection of acute myocardial inflammation, which may allow for future early clinical management of patients with myocarditis, avoiding the progression to more severe stages.

To investigate the potential of PENTIXAFOR the CHUV will recruit, on its own account, up to 60 patients in a so-called investigator initiated study (ISS). Eckert & Ziegler, owner of the rights to the CXCR4 targeted tracer used in this study, supports the CHUV team under Professor John Prior and Professor Niklaus Schaefer by providing the compound. Also, part of the CHUV team is Professor Margret Schottelius, Head of the Translational Radiopharmaceutical Sciences lab at CHUV/Agora, who was involved in the preclinical development and clinical translation of PENTIXAFOR and Dr Judith Delage, Head of the Radiopharmacy Unit, in charge, together with her team, of the clinical transfer and of the GMP internal production.

Acute myocardial inflammation is a heterogenic inflammatory disease of the heart muscle involving different clinical pathologies and outcome. The CHUV study focuses on the three entities acute cellular cardiac allograft rejection, cardiac sarcoidosis and the immune checkpoint inhibitor induced myocarditis, as non-invasive diagnosis remains challenging for these life-threatening conditions with current standards.

“Including cardiovascular indications in our prognostic development program in addition to oncology demonstrates the exciting potential of PENTIXAFOR,” comments Dr Jens Kaufmann, co-founder and general manager of Pentixapharm. “We are delighted to collaborate with an excellent centre such as the CHUV in this field, led by Dr Christel Kamani as principal investigator.”

Dr Kamani is triple-certified in cardiology (2017), internal medicine (2018) and in nuclear medicine (2022). Dr Kamani has learned all techniques of multimodality cardiovascular imaging. His research interest focuses on non-invasive multimodality tools for the detection of cardiovascular disease.

PENTIXAFOR is being developed by Eckert & Ziegler’s subsidiary Pentixapharm GmbH primarily as a superiorly sensitive diagnostic for rare blood cancers, among them myelomas, lymphoma and leukaemia.

About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

About Lausanne University Hospital
The Lausanne University Hospital (CHUV) is one of Switzerland's five university hospitals and a well-known center of medical education and research thanks to its collaboration with the Faculty of Biology and Medicine of the University of Lausanne and the Swiss Federal Institute of Technology in Lausanne (EPFL).

Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 

01.02.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
13125 Berlin
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1548853


End of News EQS News Service



show this